Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
Merck
Covington
McKesson
Mallinckrodt
Colorcon
UBS
Fish and Richardson

Generated: December 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022318

« Back to Dashboard

NDA 022318 describes RENVELA, which is a drug marketed by Genzyme and Sanofi and is included in two NDAs. It is available from four suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the RENVELA profile page.

The generic ingredient in RENVELA is sevelamer carbonate. There are thirty-two drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the sevelamer carbonate profile page.
Summary for 022318
Tradename:RENVELA
Applicant:Genzyme
Ingredient:sevelamer carbonate
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 022318
Mechanism of ActionPhosphate Chelating Activity
Suppliers and Packaging for NDA: 022318
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318 NDA AUTHORIZED GENERIC Winthrop U.S. 0955-1052 0955-1052-90 90 PACKET in 1 BOX (0955-1052-90) > 1 POWDER, FOR SUSPENSION in 1 PACKET (0955-1052-01)
RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318 NDA AUTHORIZED GENERIC Winthrop U.S. 0955-1054 0955-1054-90 90 PACKET in 1 BOX (0955-1054-90) > 1 POWDER, FOR SUSPENSION in 1 PACKET (0955-1054-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength800MG/PACKET
Approval Date:Aug 12, 2009TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Nov 25, 2019
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:➤ Sign UpPatent Expiration:Dec 6, 2030Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength2.4GM/PACKET
Approval Date:Feb 18, 2009TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Nov 25, 2019
Regulatory Exclusivity Use:NEW PATIENT POPULATION

Expired US Patents for NDA 022318

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 ➤ Sign Up ➤ Sign Up
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 ➤ Sign Up ➤ Sign Up
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-002 Feb 18, 2009 ➤ Sign Up ➤ Sign Up
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-002 Feb 18, 2009 ➤ Sign Up ➤ Sign Up
Genzyme RENVELA sevelamer carbonate FOR SUSPENSION;ORAL 022318-001 Aug 12, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Deloitte
Mallinckrodt
Cantor Fitzgerald
Cerilliant
Daiichi Sankyo
UBS
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.